Preemptive treatment of de novo donor-specific antibodies in lung transplant patients reduces subsequent risk of chronic lung allograft dysfunction or death.
Keller M, Yang S, Ponor L, Bon A, Cochrane A, Philogene M, Bush E, Shah P, Mathew J, Brown AW, Kong H, Charya A, Luikart H, Nathan SD, Khush KK, Jang M, Agbor-Enoh S.
Keller M, et al. Among authors: khush kk.
Am J Transplant. 2023 Apr;23(4):559-564. doi: 10.1016/j.ajt.2022.12.019. Epub 2023 Jan 19.
Am J Transplant. 2023.
PMID: 36732088
Free PMC article.